1. Regerier AC, Possinger K. Mammakarzinom - Manual Diagnostik und Therapie. Morphologische Grundlagen, Klassifikation, Stadieneinteilung. Berlin, 2005. Available from: https://www.onkodin.de/e2/e32345/e32485/index_print_ger.html
2. Hong YK, McMasters KM, Egger ME, Ajkay N. Ductal carcinoma in situ current trends, controversies, and review of literature. Am J Surg. 2018;216(5):998-1003.
3. Warnberg F, Garmo H, Emdin S, Hedberg V, Adwall L, Sandelin K, et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol. 2014. 32(32): p. 3613-8.
4. Doke K, Butler S, Mitchell MP. Current Therapeutic Approaches to DCIS. J Mammary Gland Biol Neoplasia. 2018;23(4):279-91.
5. Stout NK, Cronin AM, Uno H, Ozanne EM, Hassett MJ, Frank ES, et al. Estrogen-receptor status and risk of contralateral breast cancer following DCIS. Breast Cancer Res Treat. 2018;171(3):777-81.
6. Sprague BL, Trentham-Dietz A, Nichols HB, Hampton JM, Newcomb PA. Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ. Breast Cancer Res Treat. 2010;124(2):487-495.
7. Vatovec C, Erten MZ, Kolodinsky J, Brown P, Wood M, James T, et al. Ductal carcinoma in situ: a brief review of treatment variation and impacts on patients and society. Crit Rev Eukaryot Gene Expr. 2014;24(4):281-286.
8. Sourouni M. Hormonersatztherapie und duktales Carcinoma in situ. Journal für Gynäkologische Endokrinologie/ Schweiz. 2019;22 (1)
9. Lazzeroni M, Dunn BK, Pruneri G, Jereczek-Fossa BA, Orecchia R, Bonanni B, et al. Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box. Cancer Treat Rev. 2017;55:1-9.
10. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. JJ Natl Cancer Inst. 1998;90(9):697-703.
11. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol. 1999;187(4):396-402.
12. Buerger H, Otterbach F, Simon R, Schafer KL, Poremba C, Diallo R, et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol. 1999;189(4):521-526.
13. Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, et al. Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Res. 2016;18(1):22.
14. Doebar SC, Sieuwerts AM, de Weerd V, Stoop H, Martens JWM, van Deurzen CHM. Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer. Am J Pathol. 2017;187(7):1648-1655.
15. Hou L, Chen M, Wang M, Cui X, Gao Y, Xing T, et al. Systematic analyses of key genes and pathways in the development of invasive breast cancer. Gene. 2016;593(1):1-12.
16. Schultz S, Bartsch H, Sotlar K, Petat-Dutter K, Bonin M, Kahlert S, et al. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers. BMC Med Genomics. 2018;11(1):80.
17. Barsky SH, Karlin NJ. Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression. J Mammary Gland Biol Neoplasia. 2005;10(3):249-260.
18. Cowell CF, Weigelt B, Sakr RA, Ng Ng CKY, Hicks J, King TA, et al. Progression from ductal carcinoma in situ to invasive breast cancer: Revisited. Mol Oncol. 2013;7(5):859-869.
19. Sternlicht MD, Kedeshian P, Shao ZM, Safarians S, Barsky SH. The human myoepithelial cell is a natural tumor suppressor. Clin Cancer Res. 1997;3(11):1949-1958.
20. Barsky SH, Karlin NJ. Mechanisms of disease: breast tumor pathogenesis and the role of the myoepithelial cell. Nat Clin Pract Oncol. 2006;3(3):138-151.
21. Duivenvoorden HM, Rautela J, Edgington-Mitchell LE, Spurling A, Greening DW, Nowell CJ, et al. Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion. J Pathol. 2017;243(4):496-509.
22. Barsky SH, Karlin NJ. Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression. J Mammary Gland Biol Neoplasia. 2005;10(3):249-260
23. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891-906.
24. Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res. 2011;71(5):1561-1572.
25. Beguinot M, Dauplat MM, Kwiatkowski F, Lebouedec G, Tixier L, Pomel C, et al. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. BMC Cance. 2018;18(1):129.
26. Nelson AC, Machado HL, Schwertfeger KL. Breaking through to the Other Side: Microenvironment Contributions to DCIS Initiation and Progression. J Mammary Gland Biol Neoplasia. 2018;23(4):207-221.
27. Miller F.R., Santner S.J., Tait L., Dawson P.J. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J. Natl. Cancer Inst. 2000;92:1185-1186.
28. Sameni M, Anbalagan A, Olive MB, Moin K, Mattingly RR, Sloane BF. MAME models for 4D live-cell imaging of tumor: microenvironment interactions that impact malignant progression. J Vis Exp. 2012(60).
29. Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2018.
30. Osuala KO, Sameni M, Shah S, Aggarwal N, Simonait ML, Franco OE, et al. Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC cancer. 2015;15:584.
31. Sameni M, Cavallo-Medved D, Franco OE, Chalasani A, Ji K, Aggarwal N, et al. Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ. Breast Cancer Res. 2017;19(1):56.
32. Jedeszko C, Victor BC, Podgorski I, Sloane BF. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res. 2009;69(23):9148-9155.
33. Olsen CJ, Moreira J, Lukanidin EM, Ambartsumian NS. Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts. BMC Cancer. 2010;10:444.
34. Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed). 2010;15:166-179.
35. Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth. Cancers (Basel). 2015;7(4):2443-2458.
36. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8(2):98-101.
37. Slany A, Bileck A, Muqaku B, Gerner C. Targeting breast cancer-associated fibroblasts to improve anti-cancer therapy. Breast. 2015;24(5):532-8.
38. Groessl M, Slany A, Bileck A, Gloessmann K, Kreutz D, Jaeger W, et al. Proteome profiling of breast cancer biopsies reveals a wound healing signature of cancer-associated fibroblasts. J Proteome Res. 2014;13(11):4773-82.
39. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012;2(12):1100-8.
40. Slany A, Bileck A, Muqaku B, Gerner C. Targeting breast cancer-associated fibroblasts to improve anti-cancer therapy. Breast. 2015;24(5):532-8..